It is possible that aberrant KAT activity could be driving the acetylation of BRM in cancer, as KATs are known in certain cancer types to be hyperactive due to overexpression and the formation of hybrid/fusion proteins (32–34). The gene discussed is SMARCA2; the disease is cancer.